Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of LY4005130 in Healthy Participants
NCT06690996Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY4005130 (12 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration up to 26 Weeks. Started Nov 2024; status: completed.
02
Drugs
LY4005130
Beyond the preview
Go deeper on NCT06690996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690996.